Loading…
Join Josie offered compounded semaglutide and tirzepatide products on its website with false or misleading claims that violated FDA regulations under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The company falsely represented itself as the compounder of these drug products when it was not, and made misleading claims that the products contained "the same active ingredient" as FDA-approved brands Wegovy® and Zepbound®, implying FDA approval or safety evaluation that had not occurred. The FDA determined these misbranded products were being introduced or delivered for introduction into interstate commerce in violation of the law.